Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development, and preclinical studies, announced the acquisition of the TrueBlot IP/Western blot product line from eBioscience, Inc., an Affymetrix company.
TrueBlot reagents enable researchers involved in cancer, cell signaling, infectious disease as well as other life science disciplines to generate publication-quality data in immunoprecipitation and Western blot experiments. Western blotting, a critical assay that is a widely accepted analytical technique in both scientific research and medical diagnosis, is used to determine expression and quantitate target proteins in biological samples. The global market for Western blotting products is estimated at one billion dollars.
“The acquisition of the TrueBlot product line expands Rockland’s Western blot workflow product offerings and will allow our customers to perform protein research in a more efficient and effective manner, ultimately saving time and precious research dollars,” commented Jim Fendrick, President and CEO of Rockland Immunochemicals. “The TrueBlot brand has an excellent reputation and is widely considered best-in-class among Western blotting reagents.”
“As eBioscience continues to focus its efforts on our evolving flow cytometry, immunoassay and immunohistochemistry applications in immunology, oncology and other therapeutic areas, we are pleased that the TrueBlot product line is a strong strategic fit for the Rockland portfolio” added Don Tartre, General Manager of eBioscience.
Rockland will market the TrueBlot IP/Western blot product line on its e-commerce website and through its existing global distribution network.
Date: December 13, 2012
Source: Rockland Immunochemicals Inc.
Filed Under: Drug Discovery
